Related Experiment Video

Updated: Aug 7, 2026

4D Imaging of Protein Aggregation in Live Cells
08:59

4D Imaging of Protein Aggregation in Live Cells

Published on: April 5, 2013

Inhibition of protein misfolding and aggregation by small rationally-designed peptides

L D Estrada1, C Soto

  • 1Protein Misfolding Disorders Laboratory, George and Cynthia Mitchell Center for Alzheimer's Disease Research, Department of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.

Current Pharmaceutical Design
|July 18, 2006
PubMed

Insights

Protein misfolding disorders involve toxic protein aggregates. This review explores peptide-based drugs designed to prevent and dissolve these harmful protein clumps, offering a new therapeutic strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Human diseases, known as protein misfolding disorders, are linked to toxic fibrillar protein deposits.
  • These disorders are defined by the accumulation of misfolded protein aggregates in various tissues.
  • The pathogenesis involves the conversion of normal soluble proteins into beta-sheet-rich oligomeric structures and subsequent fibrillar aggregation.

Purpose of the Study:

  • To review the therapeutic potential of peptide-based drugs for protein misfolding disorders.
  • To describe compounds designed to target and modulate abnormal protein conformations.
  • To highlight the strategy of preventing and dissolving misfolded protein aggregates.

Main Methods:

  • Review of scientific literature on protein misfolding disorders and therapeutic peptides.
  • Analysis of peptide design principles for targeting pathogenic protein conformations.
  • Compilation of diverse compounds reported to possess anti-aggregation activity.

Main Results:

  • Peptides designed to bind specific pathogenic proteins offer a novel therapeutic approach.
  • These peptides can block or reverse abnormal protein conformational changes.
  • Various compounds have demonstrated efficacy in preventing or dissolving protein aggregates.

Conclusions:

  • Targeting protein misfolding through peptide-based therapeutics is a promising strategy.
  • Peptide drugs represent a new class of therapeutics for protein misfolding disorders.
  • Further development of these compounds could lead to effective treatments for associated diseases.

More Related Videos

Assays for the Degradation of Misfolded Proteins in Cells10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

Rapid Generation of Amyloid from Native Proteins In vitro05:48

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Related Concept Videos

Protein Folding01:25

Protein Folding

Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Folding01:22

Protein Folding

Overview
Protein Folding01:22

Protein Folding

Overview
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Molecular Chaperones and Protein Folding03:00

Molecular Chaperones and Protein Folding

The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...